Dive Brief:
- Science Corporation said Tuesday it has raised $400 million to commercialize its brain-computer interface in Europe and to prepare to launch the device in the U.S.
- The Series D funding round positions Science to expand the availability of its Prima BCI device, which received a CE mark and launched in Europe in July as a treatment for vision loss.
- Science, which aims to reach the U.S. market via the humanitarian device exemption pathway, raised $230 million in March and has tapped investors for more than $900 million in total.
Dive Insight:
The Prima system consists of a retinal implant and glasses. A camera on the Prima glasses captures and processes images and projects them onto the implant using near-infrared light. Once activated by the light, the implant stimulates nerve cells, which process the information in the retina and send it to the brain.
Prima restored central vision in patients with the eye disease geographic atrophy in a single-arm clinical trial of 38 patients. Most recipients gained 10 or more letters on an eye test and reported using the device at home for reading. Improvements persisted through 36 months of follow-up.
Science has raised $630 million since publishing the paper late last year. Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech participated in the Series D round.
After receiving its CE mark, the company began filing national reimbursement applications and activating clinical sites in Europe. Science named Germany as the likely location of the first commercial Prima implant.
Around the time of the European launch, Science received two humanitarian use device designations from the Food and Drug Administration. The designations cover the use of Prima in patients who have gone blind from advanced geographic atrophy or who have lost vision from Stargardt disease. Companies need an humanitarian use device designation before requesting approval via the humanitarian device exemption pathway.
Science will use the Series D funding to pursue FDA approval via the exemption pathway. The company has also earmarked funding for expanding its research, manufacturing and operational infrastructure, as well as to make “substantial further investments” in its biohybrid program.
The biohybrid program is developing a neural interface technology that uses living neurons to connect to the brain, potentially avoiding the risks and limitations of putting wires into the organ.